---
title: "Aligos 10-K: Revenue $2.19M, EPS (2.45) — 2025 Annual Filing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277942470.md"
description: "Aligos reported $2.186 million in revenue for 2025, a 39% decrease from the previous year, primarily due to the end of a collaboration with Amoytop and changes following a Merck agreement. The net loss improved to $(24.193) million, with a loss per share of $(2.45). A $60.184 million unrealized gain from common warrants helped reduce pre-tax losses. The company expects cash to fund operations into Q3 2026 but will need additional capital to sustain R&D programs. Key pipeline advancements include progress in clinical studies for pevifoscorvir sodium and ALG-055009."
datetime: "2026-03-05T13:15:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277942470.md)
  - [en](https://longbridge.com/en/news/277942470.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277942470.md)
---

# Aligos 10-K: Revenue $2.19M, EPS (2.45) — 2025 Annual Filing

Aligos reported $2.186 million in revenue for the year and a net loss per share of $(2.45), with revenue down 39% versus the prior year largely due to the end of a collaboration portion with Amoytop and subsequent changes following a Merck agreement. The company posted a net loss of $(24.193) million (an 82% improvement year-over-year) and a loss from operations of $(87.985) million; a $60.184 million unrealized gain from revaluation of 2023 common warrants materially reduced pre-tax loss. Cash is expected to fund operations into Q3 2026, creating near-term financing needs to sustain R&D programs.

**Financial Highlights**

-   **Revenue from customers:** $2.186 million, down 39% versus prior year.
-   **Operating income (loss):** Loss from operations of $(87.985) million.
-   **Net income (net loss):** Net loss of $(24.193) million, improved 82% versus prior year.
-   **Net income per share:** Net loss per share, basic and diluted: $(2.45).
-   **Change in fair value of 2023 Common Warrants:** $60.184 million gain that materially improved pre-tax loss.

**Business Highlights**

-   **Pipeline progress:** Advanced pevifoscorvir sodium through 96-week Phase 1 and initiated the Phase 2 B-SUPREME study, with interim analyses planned in 2026.
-   **Clinical milestones:** ALG-055009 met the Phase 2a MRI-PDFF primary endpoint with significant liver fat reductions; preclinical data showed potential weight-loss synergy in combination studies.
-   **Revenue mix shift:** Customer collaboration revenue fell roughly 39% in 2025 after the Amoytop collaboration portion ended; collaboration revenue ceased following the Merck agreement.
-   **Operational funding & grants:** Received approximately $15.3 million in NIH/NIAID funding for coronavirus programs and is seeking external or public funding to support development of ALG-097558.
-   **Liquidity and runway:** Cash is expected to fund operations into Q3 2026; the company will need to secure additional capital to avoid curtailing R&D activities.

Original SEC Filing: Aligos Therapeutics, Inc. \[ ALGS \] - 10-K - Mar. 05, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [688278.CN](https://longbridge.com/en/quote/688278.CN.md)
- [ALGS.US](https://longbridge.com/en/quote/ALGS.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [Merck ADC, licensed from China, hits mark in first big global trial](https://longbridge.com/en/news/287075287.md)
- [Allworth Financial LP Grows Stake in Merck & Co., Inc. $MRK](https://longbridge.com/en/news/286522605.md)
- [ZAWYA: Merck marks World Hypertension Day with launch of Hypertension Risk Checker](https://longbridge.com/en/news/286918607.md)
- [Health Rounds: Widely used asthma drug may improve performance of cancer immunotherapies](https://longbridge.com/en/news/286957357.md)
- [Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery](https://longbridge.com/en/news/287100303.md)